Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ГУ НЦПЗ РАМН, Москва
Список исп. литературыСкрыть список 1. Barret P, Conway S, Morga PJ. Digging deep-structure-function relationships in the melatonin receptors family. J Pineal Res 2003; 35: 221–30. 2. Boess FG, Martin IL. Molecular biology of 5-HT receptors. Neuropharmacology 1994; 33: 275–317. 3. Conway S, Caning SJ, Hoewll EHH et al. Characterization of human mt1 mt2 receptors by CRE-luciferase reporter assay. Eur J Pharmacol 2000; 390: 15–24. 4. Guilleminault C, Quera Salva MA. Impact of the melatononergic antidepressant agomelatine on sleep-wake rhytms of depressed patients. Eur Neuropsychopharmacol 2006; 16 (suppl. 4): 317. 5. Hamon M, Boyer PA, Mocaer E. new perspectives in the patholophysiolgy and treatment of affective disorders: the role of melatonin and serotonin. Medicographia 2005; 27 (3): 228–35. 6. Hanoun N, Moscaer E, Boyer PA et al. Differential effects of the novel antidepressant agomelatine (S 20098) versus fluoxetine on 5-HT2a receptors in the rat brain. Neuropharmacology 2004; 47: 515–26. 7. LЩo H, Hale A, D haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2c antagonist, in the treatment of major depressive disorder: a placebo-controlled dose study. Int Clin Psychopharmacol 2002; 17: 239–47. 8. Montgomery SA, Oli J-P, Keennedy SH. Antidepressants efficacy of agomelatine in major depressive disorder:meta-analysis of three pivotal studies. Eur Neuropsychopharmacol 2006; 16 (suppl. 4): 321. 9. Parrott AC, Hindmarch I. Factor analysis of steep evaluation questionnaire. Psychol Med 1978; 8 (2): 325–9. 10. Sharpley A, Cowen PJ. Effect of pharmacologic treatment on the sleep of depressed patients. Biol Psychiatry 1995; 37: 85–98. 11. Varcoe TJ, Kennaway DJ, Voultsois A. Activation of 5-HT2c, receptors actuely induces Per gene expression in the rat suprachiasmatic nucleus at night. Mol Brain Res 2003; 119: 192–200.